SS18 and synovial sarcoma: SSX1 is a potential target for miR-143, as predicted by miRBase and Target Scan 3.1. As the fusion protein SYT-SSX1 is characteristic of synovial sarcoma, miR-143 downregulation may contribute to formation of this oncoprotein [58].